CytoMed Therapeutics Ltd. (GDTC): Price and Financial Metrics Recent IPO
GDTC Price/Volume Stats
| Current price | $3.50 | 52-week high | $9.25 |
| Prev. close | $3.50 | 52-week low | $2.36 |
| Day low | $3.50 | Volume | 3,353 |
| Day high | $3.71 | Avg. volume | 294,167 |
| 50-day MA | $3.73 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 38.29M |
GDTC Stock Price Chart Interactive Chart >
Latest GDTC News From Around the Web
Below are the latest news stories about CYTOMED THERAPEUTICS LTD that investors may wish to consider to help them evaluate GDTC as an investment opportunity.
CytoMed Expands Research Collaboration into China After Entering Into MOUCytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced entering into a Memorandum of Understanding (MOU) with China-based Hangzhou CNK Therapeutics Co., Ltd. (CNK). |
CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor SummitSingapore, Singapore--(Newsfile Corp. - August 17, 2023) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company") announced today it will be presenting at the August 24th, 2023 virtual Investor Summit.Event:August 24th Investor SummitPresentation:August 24, 2023 at 11:00am ETLocation:https://us06web.zoom.us/webinar/register/WN_lq55Oh7vTrGuASU1uYFecg 1x1s will be available for qualified investorsThe conference is completely complimentary to qualified investors. Please register at Co |
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo PersistencyCytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announces today that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd (CNK). With this agreement, CytoMed can utilize CNK's PiggyBac technology to permanently graft the Chimeric Antigen Receptor (CAR) g |
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell TechnologyCytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intell |
CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell TechnologyCytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced its exclusively-licensed CAR-gamma delta T cell technology has been granted a patent by the U.S. Patent and Trademark Office. |
GDTC Price Returns
| 1-mo | 0.57% |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...